USDM: The Data Standard Connecting Your Protocol to EDC…
Why the CDISC Unified Study Definitions Model matters for sites tired of seeing the same eligibility criteria retyped three different ways. · A protocol gets…
Posts – September 2026
Public posts from September 2026, newest first. Each heading links to the post.
What Regulators Actually Expect from AI Medical Writing…
FDA and EMA frameworks clarify when AI-generated protocols, ICFs, and study reports trigger compliance obligations beyond standard drafting. · When sponsors…
Who Owns Your AI Audit Trail? Securing Clinical Trial…
Data poisoning, model drift, and validation gaps create hidden compliance risks when AI touches trial data. Here's what inspectors will ask. · Deploying AI in…
FDA's AI Credibility Framework: What It Actually Covers…
The January 2025 draft guidance is more targeted than many believe, and explicitly excludes routine document drafting from its scope. · When FDA published its…
Infrastructure Decisions That Determine If Your Clinical…
Compliance debt starts at deployment. Why regulators care more about your architecture than your model. · Most clinical teams focus on model performance, but…
The Netherlands Is One of Europe’s Most Connected Clinical…
Seven university medical centres, strong pharma presence, EU regulatory maturity and exceptional international connectivity make the Netherlands a high value…
How Structured Clinical Intelligence Reduces Protocol…
KScribe's architecture treats trial facts as a single source of truth across regulatory documents, not separate generation tasks. · Protocol amendments now…
Italy Is Southern Europe’s Leading Clinical Research Market
IRCCS research hospitals, oncology depth, EU regulatory maturity and broad patient access make Italy one of Europe’s most important trial markets. · Italy is…
Why Prompt Engineering Falls Short in Regulated Clinical…
General-purpose AI models can't meet FDA and EMA traceability requirements without structured clinical architecture. · When clinical teams deploy…
Agentic AI vs. Copilot Tools: What the Protocol Quality…
Protocol amendments cost up to $535,000 each. The architectural difference between AI copilots and agentic systems matters for protocol quality. · Protocol…
Spain Is Europe’s Leading Clinical Trial Start Market
AEMPS speed, Barcelona and Madrid research hubs, oncology depth and strong patient access make Spain one of Europe’s most important clinical trial markets. ·…
How Protocol Amendments Cascade Through Every Trial Document
A single protocol change triggers revisions across consent forms, SAPs, IBs, and more, often taking months to implement across all sites. · When a protocol is…
Document-Centric Operations Can't Keep Up With Modern…
Rising amendment rates, longer startup times, and regulatory shifts are exposing the limits of paper-era workflows in today's data-intensive trials. · Most…
Phase 2 Protocol Design: Why Getting It Right Matters More…
Poor protocol construction is driving longer timelines and compromising Phase 3 readiness as amendment cycles stretch to 260 days. · Phase 2 represents the…
France Is Europe’s Oncology Capital for Clinical Trials
Oncology depth, national CHU networks, ANSM review pathways and Health Innovation 2030 keep France central to European clinical research. · France is one of…
Protocol Amendments: The 3-Month Timeline Risk Sites Need…
76% of protocols now require at least one amendment, adding unplanned months and significant cost to trial completion. · Most clinical trial protocols change…
Trial Watch 16: Immunology and respiratory programs move…
Edition 16 shows Phase 3 activity across atopic dermatitis, respiratory disease and immune mediated conditions. · Immunology and respiratory together…
Why Your Site's Investigator Brochure Is More Than Just…
A poorly maintained IB directly affects patient safety reporting, and recent inspections found critical failures at eight organizations. · The Investigator…
Germany Remains Europe’s Scientific Backbone for Clinical…
Deep university hospital networks, regulatory reform and world class research infrastructure keep Germany central to European clinical development. · Germany…
FHIR Plus LLMs: A Technical Path to Faster Patient…
How standardized EHR data and AI-driven eligibility parsing are addressing the structural bottlenecks slowing trial enrollment. · Most recruitment delays…
Trial Watch: Edition 16
Where conviction is building in clinical development, in real time. · Trial Watch Edition 16 captures high signal clinical development activity from August 16…
How CDISC Standards Shape AI Document Generation in…
Understanding the regulatory constraints and opportunities when AI tools generate protocols, CSRs, and datasets · AI-generated clinical documents promise…
ICH E6(R3) Moves IB Requirements to Appendix A: What Sites…
New GCP guideline repositions the Investigator's Brochure as an integral framework component, not a standalone admin document. · ICH E6(R3) formally relocated…
Trial Watch 15: Oncology studies move toward sharper…
Edition 15 highlights oncology programs using targeted trial designs, specific patient groups and late stage clinical testing. · Oncology contributes five…
AI in Pharma R&D: What the Evidence Actually Shows for…
From the first AI-assisted Phase IIa result to enrollment gains and FDA guidance, here's where the data is strong and where it's still emerging. · In June…
Trial Watch 15: Immunology programs enter a more…
Two atopic dermatitis studies and one VEXAS syndrome program show how immunology development is broadening across common and rare disease settings. ·…